摘要
大部分出现药物性肝损伤(DILI)的患者预后良好,但有11%~17%的患者会发生慢性化,6%~10%可出现急性肝衰竭,甚至死亡或需要进行肝移植。2019年我国DILI发生率为23.8/10万人年,远高于西方国家,因此对DILI的研究不容忽视。本文对近年来DILI领域的热点问题进行了总结,主要包括DILI新型诊断标志物、DILI遗传易感性、特异质型DILI体内外模型、慢性DILI的诊断、DILI治疗方案、DILI预后模型、免疫检查点抑制剂导致肝损伤等,旨在为临床工作者进一步深入研究提供参考。
Most patients with drug‐induced liver injury(DILI)have a good prognosis.However,11%‐17%of the patients will suffer from chronic DILI,and 6%‐10%will suffer from acute liver failure,even death or need for liver transplantation.In 2019,the incidence of DILI in China was 23.8/100000 person year,which was far higher than that in western countries,so the study on DILI should not be ignored.This paper summarizes the hot issues in the field of DILI in recent years,mainly including the new diagnostic markers,the genetic susceptibility,the in vivo and in vitro models of idiosyncratic DILI,the diagnosis of chronic DILI,the treatment scheme,the prognosis model,the liver injury caused by immune checkpoint inhibitors,etc.,in order to provide a reference for clinical workers in future research.
作者
王昱
赵新颜
Wang Yu;Zhao Xinyan(Liver Research Center,Beijing Friendship Hospital,Capital Medical University,National Digestive System Disease Clinical Medical Research Center,Beijing 100050,China)
出处
《药物不良反应杂志》
CSCD
2023年第2期65-68,共4页
Adverse Drug Reactions Journal
基金
国家科技部科技创新2030—“新一代人工智能”重大课题(2021ZD0113200)。
关键词
化学和药物性肝损伤
诊断
鉴别
药物筛选
Chemical and drug induced liver injury
Diagnosis,differential
Drug screening
